RespireRx Pharmaceuticals Inc. announced that it has entered into a security purchase agreement for the issuance of 250 shares of series I 8% redeemable preferred stock at a price of $100 per share for gross proceeds of $25,000 on April 5, 2023. The transaction will include two individual accredited investors. The preferred stock will pay dividend of 8% per annum, payable annually within fifteen calendar days of the end of each fiscal year of the company.

The preferred shares redemption shall happen upon the payment of an eligible payment which takes place upon the occurrence of an eligible payment event, as both terms are defined in the certificate. The preferred shares are not convertible into common shares of the company. The transaction has been approved by the board of directors of the company.

All the securities issued in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act.